display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic, hormone-sensitive prostate cancer
metastatic, hormone-sensitive prostate cancer
abiraterone plus ADT LATITUDE STAMPEDE abiraterone

Study type: